| scholarly article | Q13442814 |
| P2093 | author name string | Hayashi T | |
| Kano H | |||
| Iguchi A | |||
| Egashira K | |||
| Tsunekawa T | |||
| Matsui-Hirai H | |||
| Sumi D | |||
| Thakur NK | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endothelium | Q111140 |
| P304 | page(s) | 376-379 | |
| P577 | publication date | 2001-07-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. | |
| P478 | volume | 104 |
| Q45068304 | A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits |
| Q35603932 | ADMA and oxidative stress |
| Q38124049 | Activation of sphingosine-1-phosphate signalling as a potential underlying mechanism of the pleiotropic effects of statin therapy. |
| Q44932061 | Anti-apoptotic effect of atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac myocytes through protein kinase C activation |
| Q36337932 | Anti-inflammatory effects of statins: clinical evidence and basic mechanisms |
| Q35084723 | Beyond lipid-lowering: effects of statins on endothelial nitric oxide |
| Q39775989 | Can simvastatin improve erectile function and health-related quality of life in men aged >40 years with erectile dysfunction? Rationale and design of the Erectile Dysfunction and Statins (EDS) Trial [ISRCTN66772971](1). |
| Q39604956 | Can simvastatin improve erectile function and health-related quality of life in men aged ≥40 years with erectile dysfunction? Results of the Erectile Dysfunction and Statins Trial [ISRCTN66772971]. |
| Q36081210 | Clinical impact of vasomotor function assessment and the role of ACE-inhibitors and statins |
| Q37645663 | Current pharmacotherapeutic concepts for the treatment of cardiovascular disease in diabetics |
| Q35804090 | Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects |
| Q42380274 | Early Statins after Intravenous or Endovascular Recanalization Is Beneficial Regardless of Timing, Intensity, and Stroke Mechanism. |
| Q36537985 | Early changes in arterial structure and function following statin initiation: quantification by magnetic resonance imaging |
| Q34979669 | Early statin therapy for acute coronary syndromes |
| Q44454389 | Effect of atorvastatin (80 mg) on recurrent ischemia in unstable angina pectoris or non-ST-elevation acute myocardial infarction |
| Q44384630 | Effect of atorvastatin on endothelium-dependent vasodilation in patients with coronary artery disease |
| Q46495805 | Effect of correcting serum cholesterol levels on erectile function in patients with vasculogenic erectile dysfunction |
| Q93118323 | Effects of combined statin and ACE inhibitor therapy on endothelial function and blood pressure in essential hypertension - a randomised double-blind, placebo controlled crossover study |
| Q46775575 | Effects of fluvastatin, an HMG-CoA reductase inhibitor, on serum levels of interleukin-18 and matrix metalloproteinase-9 in patients with hypercholesterolemia. |
| Q80505490 | Endothelial dysfunction in diabetes mellitus |
| Q33776230 | Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment |
| Q30547579 | Ezetimibe potently reduces vascular inflammation and arteriosclerosis in eNOS-deficient ApoE ko mice. |
| Q38235417 | HMG-CoA reductase inhibitors (statins), inflammation, and endothelial progenitor cells-New mechanistic insights of atherosclerosis |
| Q34914125 | IL-1β and IL-18: inflammatory markers or mediators of hypertension? |
| Q80675789 | Immediate effect of fluvastatin on lipid levels in acute coronary syndrome |
| Q34036274 | Immediate effect of intensive atorvastatin therapy on lipid parameters in patients with acute coronary syndrome |
| Q39404486 | Impact of atorvastatin treatment in first-degree relatives of patients with premature coronary artery disease with endothelial dysfunction: a double-blind, randomized, placebo-controlled crossover trial. |
| Q45157686 | Impaired endothelium-dependent and -independent vasodilation in elderly patients with chronic heart failure |
| Q79369236 | Increased plasma thioredoxin in patients with acute myocardial infarction |
| Q35624965 | Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case-control study |
| Q35197114 | Isoprenoid metabolism and the pleiotropic effects of statins |
| Q35989396 | Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy. |
| Q47776394 | Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities. |
| Q37030681 | Microcirculation and oxidative stress |
| Q26737722 | Modifying Risk Factors in the Management of Erectile Dysfunction: A Review |
| Q35936423 | Molecular, cellular and functional imaging of atherothrombosis |
| Q35375986 | NOX1, 2, 4, 5: counting out oxidative stress |
| Q44228337 | Neuroprotective effects of statins may not be related to total and low-density lipoprotein cholesterol lowering |
| Q35115544 | New Insights on Oxidative Stress and Diabetic Complications May Lead to a “Causal” Antioxidant Therapy |
| Q37421169 | Novel approaches to improving endothelium-dependent nitric oxide-mediated vasodilatation |
| Q34628242 | Pitavastatin: evidence for its place in treatment of hypercholesterolemia |
| Q73349526 | Role of hyaluronic acid glycosaminoglycans in shear-induced endothelium-derived nitric oxide release |
| Q77875818 | Role of statin drugs in acute coronary syndromes |
| Q47685461 | Short-term therapy with relatively low-dose cerivastatin improves endothelial function independently of its lipid-lowering effect: Evaluation of brachial artery vasodilatation using B-mode ultrasound imaging |
| Q45183711 | Simvastatin improved arterial compliance in high-risk patients. |
| Q30769745 | Simvastatin improves the sexual health-related quality of life in men aged 40 years and over with erectile dysfunction: additional data from the erectile dysfunction and statin trial |
| Q40333234 | Simvastatin treatment improves endothelial function and increases fibrinolysis in patients with hypercholestrolemia. |
| Q43215640 | Statins and modulation of oxidative stress. |
| Q36768488 | Statins as first-line therapy for acute coronary syndrome? |
| Q34481748 | Statins in the 21st century: end of the simple story? |
| Q37276466 | Statins in the first-line therapy of acute coronary syndrome - similar to aspirin? |
| Q42331896 | Statins in type 2 diabetes mellitus: target on lipids and vascular wall function |
| Q42487652 | Statins reverse renal inflammation and endothelial dysfunction induced by chronic high salt intake |
| Q36088044 | Statins: immunomodulators for autoimmune rheumatic disease? |
| Q55279804 | Strategies to decrease oxidative stress biomarker levels in human medical conditions: A meta-analysis on 8-iso-prostaglandin F2α. |
| Q44140689 | Surrogate end points as a clinical and public health problem. The cerivastatin case |
| Q26863500 | Targeting NADPH oxidases in vascular pharmacology |
| Q36892494 | The impact of insulin resistance on endothelial function, progenitor cells and repair |
| Q36536154 | The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation |
| Q26823131 | The role of statins in erectile dysfunction: a systematic review and meta-analysis |
| Q35744631 | The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach |
| Q33870395 | Therapeutic interventions and oxidative stress in diabetes |
| Q36892489 | Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus. |
| Q37104540 | Vascular compliance in the cardiometabolic syndrome |
| Q34714365 | Venous and arterial disease in inflammatory bowel disease |
| Q36833145 | Very rapid effect of pitavastatin on microvascular function in comparison to rosuvastatin: reactive hyperemia peripheral arterial tonometric study |
| Q35001052 | Why might statins prevent venous thromboembolism: what needs to be done to know more? |
Search more.